Q32 Bio Investors

38 investors on Angel Roster list Q32 Bio in their portfolio. Most are venture capital firms and private equity firms, the most common stage is Series A and the largest groups are based in the United States, the United Kingdom and Israel.

Investors are matched on the company name in their portfolio, so companies that share the name Q32 Bio can appear together.

Investors listed
38
With verified email
55%
Most common stage
Series A
Top location
United States

Updated October 13, 2026 · How we compile this data

Top 38 Q32 Bio investors

The most complete profiles first. Showing 38 of 38.

  • David BonitaVerified

    Venture Capital, Private Equity Firm, Investor · United States

    SeedSeries AHealth CareInvestment ManagementLife ScienceInformation Technology (IT)

    Portfolio: Edgewise Therapeutics, Syros Pharmaceuticals, Yisheng Biopharma, Evox Therapeutics and 93 more

    Verified email available

  • Geoffrey HsuVerified

    Venture Capital, Private Equity Firm, Investor · United States

    SeedSeries AHealth CareInvestment ManagementLife ScienceInformation Technology (IT)

    Portfolio: Edgewise Therapeutics, Syros Pharmaceuticals, Yisheng Biopharma, Evox Therapeutics and 87 more

    Verified email available

  • Jernej GodecVerified

    Venture Capital, Investor · United States

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Magenta Therapeutics, Remix Therapeutics, Vigil Neuroscience, Quartet Medicine and 62 more

    Verified email available

  • Ken HaasVerified

    Venture Capital, Advisor, Investor · United States

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Verified email available

  • Kevin BittermanVerified

    Venture Capital, Investor · United States

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Magenta Therapeutics, Remix Therapeutics, Vigil Neuroscience, Quartet Medicine and 70 more

    Verified email available

  • Louis BernemanVerified

    Venture Capital, University Program, Entrepreneurship Program · United States

    Series AHealth CareGeneticsPaymentsCybersecurity

    Portfolio: CounterFlow, Infinite Uptime, Modis Therapeutics, Vor Biopharma and 64 more

    Verified email available

  • Manny StockmanVerified

    Venture Capital, University Program, Entrepreneurship Program · United States

    Series AHealth CareGeneticsPaymentsCybersecurity

    Portfolio: CounterFlow, Infinite Uptime, Modis Therapeutics, Vor Biopharma and 64 more

    Verified email available

  • Robert AdelsonVerified

    Venture Capital, University Program, Investor · United States

    Series AHealth CareGeneticsPaymentsCybersecurity

    Portfolio: CounterFlow, Infinite Uptime, Modis Therapeutics, Vor Biopharma and 65 more

    Verified email available

  • andrew sinclairVerified

    Venture Capital, Private Equity Firm, Investor · United Kingdom

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Verified email available

  • Alex HardingVerified

    Venture Capital · United States

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Magenta Therapeutics, Remix Therapeutics, Vigil Neuroscience, Quartet Medicine and 62 more

    Verified email available

  • Anurag AgarwalVerified

    Venture Capital, University Program, Entrepreneurship Program · United States

    Health CareGeneticsPaymentsCybersecurity

    Portfolio: CounterFlow, Infinite Uptime, Modis Therapeutics, Vor Biopharma and 64 more

    Verified email available

  • Jason P. HaflerVerified

    Corporate Venture Capital · United States

    Health CareWellnessWomen FoundedLife Science

    Portfolio: Proteostasis Therapeutics, Science 37, ImmuneXcite, Aetion and 37 more

    Verified email available

  • Jason RhodesVerified

    Venture Capital, Private Equity Firm · United States

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Magenta Therapeutics, Remix Therapeutics, Vigil Neuroscience, Quartet Medicine and 62 more

    Verified email available

  • Jonathan SilversteinVerified

    Private Equity Firm · United States

    Health CareLife ScienceInformation Technology (IT)Mobile

    Portfolio: Edgewise Therapeutics, Syros Pharmaceuticals, Yisheng Biopharma, Evox Therapeutics and 87 more

    Verified email available

  • Jonathan WangVerified

    Private Equity Firm · China

    Health CareLife ScienceInformation Technology (IT)Mobile

    Portfolio: Edgewise Therapeutics, Syros Pharmaceuticals, Yisheng Biopharma, Evox Therapeutics and 87 more

    Verified email available

  • Laia CrespoVerified

    Venture Capital, Corporate Venture Capital, Investor · France

    Health CareWellnessWomen FoundedLife Science

    Portfolio: Proteostasis Therapeutics, Science 37, ImmuneXcite, Aetion and 37 more

    Verified email available

  • Matt CohenVerified

    Venture Capital, University Program · United States

    Health CareGeneticsPaymentsCybersecurity

    Portfolio: CounterFlow, Infinite Uptime, Modis Therapeutics, Vor Biopharma and 64 more

    Verified email available

  • Rishi GuptaVerified

    Private Equity Firm · United States

    Health CareInvestment ManagementLife ScienceInformation Technology (IT)

    Portfolio: Edgewise Therapeutics, Syros Pharmaceuticals, Yisheng Biopharma, Evox Therapeutics and 87 more

    Verified email available

  • Shelley ChuVerified

    Venture Capital · United States

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Verified email available

  • Tim HainesVerified

    Venture Capital · United Kingdom

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Verified email available

  • Bali Muralidhar

    Venture Capital, Private Equity Firm, Investor · United Kingdom

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 69 more

    Contact details available

  • Brian Gallagher, Jr.

    Venture Capital, Investor · United States

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Aileron Therapeutics, Amarin and 67 more

    Contact details available

  • Carter Neild

    Venture Capital, Private Equity Firm, Investor · United States

    SeedSeries AHealth CareInvestment ManagementLife ScienceInformation Technology (IT)

    Portfolio: Edgewise Therapeutics, Syros Pharmaceuticals, Yisheng Biopharma, Evox Therapeutics and 87 more

    Contact details available

  • Chau Khuong

    Venture Capital, Private Equity Firm, Investor · United States

    SeedSeries AHealth CareLife ScienceInformation Technology (IT)Mobile

    Portfolio: Edgewise Therapeutics, Syros Pharmaceuticals, Gennao Bio, Yisheng Biopharma and 89 more

    Contact details available

  • Kurt von Emster

    Venture Capital, Private Equity Firm, Investor · United States

    Series BHealth CareWomen FoundedInvestment ManagementLife Science

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Contact details available

  • Marc Singer

    Venture Capital, University Program, Entrepreneurship Program · United States

    Series AHealth CareGeneticsPaymentsCybersecurity

    Portfolio: CounterFlow, Infinite Uptime, Modis Therapeutics, Vor Biopharma and 69 more

    Contact details available

  • Scotland Stevens

    Venture Capital, Private Equity Firm, Investor · United States

    SeedSeries AHealth CareInvestment ManagementLife ScienceInformation Technology (IT)

    Portfolio: Edgewise Therapeutics, Syros Pharmaceuticals, Yisheng Biopharma, Evox Therapeutics and 87 more

    Contact details available

  • Vin Miles

    Venture Capital, Investor · United States

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Contact details available

  • William Harrington

    Venture Capital, University Program, Investor · United States

    Series AHealth CareGeneticsPaymentsCybersecurity

    Portfolio: CounterFlow, Infinite Uptime, Modis Therapeutics, Vor Biopharma and 71 more

    Contact details available

  • Anat Naschitz

    Private Equity Firm · Israel

    Health CareLife ScienceInformation Technology (IT)Mobile

    Portfolio: Edgewise Therapeutics, Syros Pharmaceuticals, Yisheng Biopharma, Evox Therapeutics and 87 more

    Contact details available

  • Daniel Mansuri

    Corporate Venture Capital · United States

    Health CareWellnessWomen FoundedLife Science

    Portfolio: Proteostasis Therapeutics, Science 37, ImmuneXcite, Aetion and 37 more

    Contact details available

  • Erez Chimovits

    Private Equity Firm · Israel

    Health CareInvestment ManagementLife ScienceInformation Technology (IT)

    Portfolio: Edgewise Therapeutics, Syros Pharmaceuticals, Yisheng Biopharma, Evox Therapeutics and 87 more

    Contact details available

  • Jean

    Venture Capital · United States

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Magenta Therapeutics, Remix Therapeutics, Vigil Neuroscience, Quartet Medicine and 62 more

    Contact details available

  • John Heard

    Venture Capital, Private Equity Firm · United Kingdom

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Contact details available

  • Kirsten Leute

    Venture Capital, University Program · United States

    Health CareGeneticsPaymentsCybersecurity

    Portfolio: CounterFlow, Infinite Uptime, Modis Therapeutics, Vor Biopharma and 64 more

    Contact details available

  • Sarah Shackelton

    Venture Capital · United Kingdom

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Contact details available

  • Steven Robinette

    Venture Capital · United States

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Magenta Therapeutics, Remix Therapeutics, Vigil Neuroscience, Quartet Medicine and 62 more

    Contact details available

  • Diyong XuVerified

    Venture Capital, Investor · United States

    SeedSeries AHealth CareInvestment ManagementBiotechnologyElectronic Health Records (EHR)

    Portfolio: Q32 Bio

    Verified email available

Frequently asked questions

How many Q32 Bio investors are on Angel Roster?

Angel Roster lists 38 Q32 Bio investors. 21 of them (55%) include a verified email address.

What types of investors are they?

The most common investor types are Venture Capital Firms (31), Private Equity Firms (19) and University Program Investors (8). An investor can have more than one type, for example an angel who is also a venture partner.

Which stages do Q32 Bio investors invest in?

Among those that list a stage, the most common are Series A (11), Series B (8) and Seed (6).

Where are Q32 Bio investors based?

Most are based in the United States (29), the United Kingdom (5) and Israel (2).

Which companies have Q32 Bio investors backed?

The most-backed portfolio companies among them are Scorpion Therapeutics (26), Verona Pharma (20), X4 Pharmaceuticals (20), UNUM Therapeutics (19) and Cleave Therapeutics (18).

How do I contact Q32 Bio investors?

Create a free Angel Roster account to search and filter all 38, then unlock verified emails and LinkedIn profiles on a paid plan. Every plan starts with a 3-day free trial.